Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above

NCT05408312 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

234

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Pneumonia

Interventions

BIOLOGICAL: Experimental Vaccine 1
BIOLOGICAL: Experimental Vaccine 2
BIOLOGICAL: Experimental Vaccine 3
BIOLOGICAL: placebo

Sponsor

National Vaccine and Serum Institute, China

Collaborators

[object Object]
[object Object]